Ocugen is a biotechnology business based in the US. Ocugen stocks (OCGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.65 – an increase of 12.12% over the previous week. Ocugen employs 15 staff and has a market cap (total outstanding stock value) of $1.7 billion.
How to buy shares in Ocugen
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – OCGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Is it a good time to buy Ocugen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
What's in this guide?
- Can I buy shares in Ocugen?
- Has coronavirus impacted Ocugen shares?
- Ocugen shares summary
- Compare share dealing platforms
- Is Ocugen stock a buy or sell?
- Ocugen performance over time
- Can I short Ocugen shares?
- Ocugen's financials
- How volatile are Ocugen shares?
- Does Ocugen pay a dividend?
- Have Ocugen shares ever split?
- Other common questions
How has Coronavirus impacted Ocugen's stock price?
Since the stock market crash in March caused by coronavirus, Ocugen's stock price has had significant positive movement.
Its last market close was $9.34, which is 94.46% up on its pre-crash value of $0.517 and 3,492.31% up on the lowest point reached during the March crash when the stocks fell as low as $0.26.
If you had bought $1,000 worth of Ocugen stocks at the start of February 2020, those stocks would have been worth $553.46 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $17,961.57.
Ocugen stock priceUse our graph to track the performance of OCGN stocks over time.
Ocugen shares at a glance
|Latest market close||$9.34|
|52-week range||$0.25 - $16.20|
|50-day moving average||$7.70|
|200-day moving average||$7.92|
|Wall St. target price||$8.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.27|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Ocugen price performance over time
|1 week (2021-10-19)||12.12%|
|1 month (2021-09-22)||N/A|
|3 months (2021-07-26)||36.95%|
|6 months (2021-04-26)||-19.41%|
|1 year (2020-10-26)||2,938.39%|
|2 years (2019-10-25)||430.68%|
|3 years (2018-10-26)||1,091.48%|
|5 years (2016-10-26)||214.48%|
|Operating margin TTM||10146504%|
|Gross profit TTM||$-5,099,160|
|Return on assets TTM||-32.56%|
|Return on equity TTM||-72.19%|
|Market capitalisation||$1.7 billion|
TTM: trailing 12 months
Shorting Ocugen shares
There are currently 53.1 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 0.6% up from 52.8 million last month.
There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.
Ocugen's "short interest ratio" (SIR)
Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 12.0 million). Ocugen's SIR currently stands at 4.42. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 4420 shares are currently held short.
However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.27% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 270 shares are currently held short) or 0.2743% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 274 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.
Ocugen share dividends
We're not expecting Ocugen to pay a dividend over the next 12 months.
Have Ocugen's shares ever split?
Ocugen's shares were split on a 1:60 basis on 30 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.
Ocugen share price volatility
Over the last 12 months, Ocugen's shares have ranged in value from as little as $0.2501 up to $16.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocugen's is 4.3003. This would suggest that Ocugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Ocugen, Inc. , a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Stocks similar to Ocugen
Frequently asked questions
Ocugen in the news
Ocugen Inc. stock rises Monday, outperforms market
2 Biotech Stocks That Could Go Parabolic This Week
2 Biotech Stocks That Could Go Parabolic This Week
More on investing
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Steps to owning and managing Cue Health stocks, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
More guides on Finder
How to buy AirSculpt Technologies (AIRS) stock in Canada when it goes public
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
How to buy Candela Medical (CDLA) stock in Canada when it goes public
Everything we know about the Candela Medical IPO, plus information on how to buy in.
How to buy Ensemble Health Partners (ENSB) stock in Canada when it goes public
Everything we know about the Ensemble Health Partners IPO, plus information on how to buy in.
How to buy Fluence Energy (FLNC) stock in Canada when it goes public
Everything we know about the Fluence Energy IPO, plus information on how to buy in.
How to buy GlobalFoundries (GFS) stock in Canada when it goes public
Everything we know about the GlobalFoundries IPO, plus information on how to buy in.
How to buy LianBio (LIAN) stock in Canada when it goes public
Everything we know about the LianBio IPO, plus information on how to buy in.
How to buy Rent the Runway (RENT) stock in Canada when it goes public
Everything we know about the Rent the Runway IPO, plus information on how to buy in.
How to buy Solo Brands (DTC) stock in Canada when it goes public
Everything we know about the Solo Brands IPO, plus information on how to buy in.
How to buy Udemy (UDMY) stock in Canada when it goes public
Everything we know about the Udemy IPO, plus information on how to buy in.
How to buy Arteris (AIP) stock in Canada when it goes public
Everything we know about the Arteris IPO, plus information on how to buy in.